Cadence Capital Management LLC grew its stake in Recro Pharma, Inc. (NASDAQ:REPH) by 34.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 167,637 shares of the specialty pharmaceutical company’s stock after purchasing an additional 43,146 shares during the quarter. Cadence Capital Management LLC owned approximately 0.88% of Recro Pharma worth $1,505,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of REPH. OxFORD Asset Management LLP raised its position in shares of Recro Pharma by 364.3% in the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after purchasing an additional 159,619 shares during the period. State Street Corp bought a new position in shares of Recro Pharma in the second quarter valued at about $1,047,000. Northern Trust Corp raised its position in shares of Recro Pharma by 428.5% in the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after purchasing an additional 144,676 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Recro Pharma by 787.4% in the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock valued at $911,000 after purchasing an additional 114,960 shares during the period. Finally, JT Stratford LLC bought a new position in shares of Recro Pharma in the second quarter valued at about $704,000. 61.55% of the stock is currently owned by institutional investors.

In related news, major shareholder Healthcare Master Fun Broadfin sold 222,616 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $9.58, for a total transaction of $2,132,661.28. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders have sold 544,813 shares of company stock worth $5,191,579. 21.60% of the stock is owned by insiders.

Several brokerages have recently weighed in on REPH. Zacks Investment Research lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Piper Jaffray Companies reissued a “buy” rating and issued a $11.00 price objective on shares of Recro Pharma in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Recro Pharma presently has an average rating of “Buy” and a consensus target price of $11.65.

Recro Pharma, Inc. (NASDAQ:REPH) opened at $9.91 on Friday. Recro Pharma, Inc. has a 1 year low of $5.81 and a 1 year high of $9.96. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/02/recro-pharma-inc-reph-shares-bought-by-cadence-capital-management-llc.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma, Inc. (NASDAQ:REPH).

Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.